Windlas Biotech Limited has informed the Exchange about Investor Presentation
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech reported FY25 revenue of Rs 759.9 crore, up 20.4% YoY, with Q4 FY25 revenue of Rs 202.7 crore (18.3% YoY growth) marking the 9th straight quarter of record revenue. EBITDA grew 20% YoY to Rs 94.1 crore with margins sustained at 12.4%, while PAT stood at Rs 61 crore and the company achieved its highest-ever post-listing EPS of Rs 29.19. The Generic Formulations CDMO vertical (73% of revenue) grew 15% YoY to Rs 555.1 crore, Trade Generics & Institutional (22% of revenue) surged 41% to Rs 172.1 crore, and Exports rose 19% to Rs 32.6 crore. The company is net debt-free with Rs 213 crore in liquidity, working capital days at 14, ROCE of 25% and ROE of 23%, and proposed a dividend of Rs 5.8 per share for FY25. Key growth drivers mentioned include ramp-up of the new Injectable facility, Plant-2 extension operational from Q4 FY25, and modernization of the recently acquired Plant-6 oral solids facility.
Strong results with 20% revenue and EBITDA growth, record EPS, and a higher dividend should be viewed positively by shareholders. The capacity expansion across Injectables, Plant-2 and Plant-6 provides visible growth runway, though the slight dip in PAT margin (8.0% vs 9.2%) due to higher depreciation from new facilities is a watchpoint.